CRISPR Therapies Market Research 2024: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, Impact of Drugs
14 juin 2024 06h15 HE
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CRISPR therapies - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "CRISPR Therapies - Pipeline...
CRISPR Technology Global Strategic Research Report 2024
14 juin 2024 05h30 HE
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CRISPR Technology - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for CRISPR...
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
02 juin 2024 19h00 HE
|
Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER...
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
30 mai 2024 16h01 HE
|
Caribou Biosciences, Inc.
BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
29 mai 2024 15h27 HE
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature...
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
29 mai 2024 08h30 HE
|
Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
29 mai 2024 02h30 HE
|
Cytosurge AG
CellEDIT uses FluidFM for precise nuclear CRISPR/Cas9 injection, boosting efficiency by controlling RNP amounts, preserving traits in edited CHO-K1 cells.
Tome Biosciences Presented Data on its Programmable Genomic Integration Technologies at ASGCT
10 mai 2024 06h00 HE
|
Tome Biosciences
Tome presented data updates on its programmable genomic integration technologies at ASGCT.
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update
07 mai 2024 16h05 HE
|
Caribou Biosciences, Inc.
-- Advancing CB-010 ANTLER Phase 1 trial in 2L LBCL; initial dose expansion data to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting -- -- Expanding into...
Aanastra Inc to Showcase its Peptide-RNA Therapeutics Technology in Multiple Presentations at the American Society for Gene and Cell Therapies (ASGCT) Annual Meeting 2024
02 mai 2024 06h30 HE
|
Aanastra Inc
Aanastra showcases its peptide-RNA therapeutics targeting p53, KRAS and BRCA-1 driven cancers, hemophilia A and PCSK9 for hypercholestrolemia at ASGCT